Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Rio Piedras, Puerto Rico Clinical Trials

A listing of Rio Piedras, Puerto Rico clinical trials actively recruiting patients volunteers.

RESULTS

Found (76) clinical trials

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

A randomized, multicenter, double-blind, placebo- controlled parallel-group study to determine the efficacy and safety of QAW039, compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult and adolescent ( 12 years) patients with uncontrolled asthma with respect to change from baseline in forced expiratory volume in 1 second ...

Phase

4.12 miles

Learn More »

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive HIV-1 and Hepatitis B Co-Infected Adults

The primary objective of this study is to evaluate the efficacy of fixed-dose combination (FDC) of bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + emtricitabine/tenofovir disoproxil fumarate (F/TDF) in HIV and hepatitis B virus (HBV) treatment naive, HIV-1 and HBV co-infected adults.

Phase

4.12 miles

Learn More »

A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis

The purpose of this study is to evaluate the efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis.

Phase

4.12 miles

Learn More »

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Study duration per participant is approximately 1 year in Group 1 and Group 2, and 10 months in Group 3 and Group 4. This duration includes a safety follow-up contact at 6 months after the last vaccination.

Phase

4.34 miles

Learn More »

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Healthy infants will be enrolled and randomized to receive either 4 doses of MenACYW conjugate vaccine or 4 doses of the licensed control vaccine, MENVEO. All participants will receive routine vaccines as per the Advisory Committee on Immunization Practices (ACIP) recommendations. All participants will be assessed for immunogenicity at baseline ...

Phase

4.34 miles

Learn More »

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Approximately 16 months, which includes a safety follow-up contact at 6 months after the final vaccination

Phase

4.34 miles

Learn More »

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

HPV-301 is a prospective, randomized, double-blind, placebo controlled Phase 3 study to determine the efficacy, safety, and tolerability of VGX-3100 administered by intramuscular (IM) injection followed by electroporation (EP) delivered with CELLECTRA 5PSP in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade ...

Phase

4.37 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)

This study comprises three sub-studies. The objective of sub-study 1 is to characterize the dose-response, efficacy, and safety of upadacitinib compared to placebo in inducing clinical remission in order to identify the induction dose of upadacitinib for further evaluation in sub-study 2. The objective of sub-study 2 is to evaluate ...

Phase

4.37 miles

Learn More »

A Study to Evaluate the Interchangeability of V114 and Prevnar 13 in Healthy Infants (V114-027/PNEU-DIRECTION)

This study is designed to evaluate the safety, tolerability, and immunogenicity of V114 and Prevnar 13 in healthy infants switched from Prevnar 13 to V114 during the Pneumococcal Conjugate Vaccine (PCV) immunization schedule.

Phase

4.37 miles

Learn More »

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis

The objective of this study is to evaluate the efficacy and safety of Upadacitinib compared to placebo in inducing clinical remission (per Adapted Mayo score) in participants with moderately to severely active ulcerative colitis (UC).

Phase

4.37 miles

Learn More »